Impact News +++ ABIONYX Pharma Is Launching a Capital Increase With Cancellation of Preferential Subscription Rights in... (Business Wire) +++ ABIONYX Aktie -4,27%

NUWELLIS Aktie

>NUWELLIS Performance

1 Woche: 0%

1 Monat: 0%

3 Monate: 0%

6 Monate: 0%

1 Jahr: 0%

laufendes Jahr: 0%

>NUWELLIS Aktie

Name:

NUWELLIS COM NEW DL-,0001

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US67113Y7022 / A41BZT

Symbol/ Ticker:

22S0 (Frankfurt) / NUWE (NASDAQ)

Kürzel:

FRA:22S0, ETR:22S0, 22S0:GR, NASDAQ:NUWE

Index:

Webseite:

https://www.nuwellis.com/

Profil:

Marktkapitalisierung:

3.22 Mio. EUR

Unternehmenswert:

0.92 Mio. EUR

Umsatz:

6.96 Mio. EUR

EBITDA:

-9.2 Mio. EUR

Nettogewinn:

-14.11 Mio. EUR

Gewinn je Aktie:

-91.7 EUR

Schulden:

0.33 Mio. EUR

Liquide Mittel:

2.64 Mio. EUR

Operativer Cashflow:

-7.91 Mio. EUR

Bargeldquote:

0.88

Umsatzwachstum:

-8.93%

Gewinnwachstum:

-8.95%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

NUWELLIS

Letzte Datenerhebung:

16.12.25

>NUWELLIS Kennzahlen

Aktien/ Unternehmen:

Aktien: 0.9 Mio. St.

Frei handelbar: 97.7%

Leerverk. Aktien: 3.1%

Rückkaufquote: -280.38%

Mitarbeiter: 38

Umsatz/Mitarb.: 0.2 Mio. EUR

Analysten:

Analystenrating: Neutral

Kursziel: -

Bewertung:

KGV: -

KGV lG: -

KUV: 0.25

KBV: 0.8

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: 59.07%

Gewinnmarge: -202.83%

Operative Marge: -135.28%

Managementeffizenz:

Gesamtkaprendite: -225.22%

Eigenkaprendite: -467.14%

>NUWELLIS Peer Group

Es sind 599 Aktien bekannt.

>NUWELLIS Chart & Kurs - NASDAQ

>NUWELLIS News

09.12.25 - 14:18	Lenox Hill Hospital Study Highlights the Broad Utility of Aquadex in Managing Fluid Overload Across Critical Care Settings (GlobeNewswire EN)
	Findings reinforce Nuwellis' leadership in precision ultrafiltration for patients with acute kidney injury and fluid overload. Findings reinforce Nuwellis' leadership in precision ultrafiltration for patients with acute kidney injury and fluid overload....

04.12.25 - 14:18	Nuwellis Continues Clinician-Driven Growth in Pediatric Care with a Leading Hospital in the Northeast U.S. (GlobeNewswire EN)
	Pediatric nephrology and cardiology teams continue to seek out Aquadex for safe, precise fluid management in complex cases Pediatric nephrology and cardiology teams continue to seek out Aquadex for safe, precise fluid management in complex cases...

12.11.25 - 16:06	Earnings Call Transkript: Nuwellis Q3 2025 mit Umsatzrückgang – Aktie gibt nach (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

12.11.25 - 14:24	Nuwellis GAAP EPS of $0.56, revenue of $2.22M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

12.11.25 - 14:18	Nuwellis Reports Third Quarter 2025 Results and Continued Operational Momentum (GlobeNewswire EN)
	Company delivers steady performance and achieves key milestones across critical care, pediatrics, and hospital-based outpatient therapy Company delivers steady performance and achieves key milestones across critical care, pediatrics, and hospital-based outpatient therapy...

11.11.25 - 18:15	Nuwellis Q3 Earnings Preview (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

10.11.25 - 15:03	Nuwellis Receives Notice of Allowance of a New U.S. Patent Strengthening Vivian™ Pediatric System with Advanced Clamp Safety Technology (GlobeNewswire EN)
	Continues momentum in pediatric innovation and platform development Continues momentum in pediatric innovation and platform development...

23.10.25 - 15:03

Nuwellis, Inc. To Report Third Quarter 2025 Financial Results on November 12, 2025 (GlobeNewswire EN)

MINNEAPOLIS, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardio-renal conditions, addressing the critical interplay between the heart and kidneys, today announced that it will release financial results for the third quarter 2025 on November 12, 2025. Nuwellis will host a conference call and webcast at 9:00 AM ET to discuss its financial results and provide a general business update....

30.09.25 - 14:48	Nuwellis Announces 92% Survival in Children with Acute Kidney Injury (AKI), Fluid Overload or Congenital Kidney Failure Following Treatment with Aquadex® (GlobeNewswire EN)
	ULTRA-Peds Registry Demonstrate 92% Treatment Survival in Children with AKI Fluid Overload or Congenital Kidney Failure...

18.09.25 - 15:03	Nuwellis Receives New US Patent Reinforcing Vivian™ Pediatric Device Focused on Safer, More Precise Ultrafiltration (GlobeNewswire EN)
	EDEN PRAIRIE, Minn., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc., a fluid management company, today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 12,415,021 on September 16, 2025, based on Application No. 18/298,860....

17.09.25 - 16:21	Nuwellis, Inc. Participates in a Virtual Investor “What This Means” Segment (GlobeNewswire EN)
	Watch the “What This Means” segment here...

04.09.25 - 14:18	Nuwellis Introduces New 24-Hour Aquadex™ Circuit to Support Hospital-Based Outpatient and Short-Term Fluid Management (GlobeNewswire EN)
	Nuwellis, Inc., a fluid management company, announced plans to introduce a new 24-hour circuit for Aquadex therapy in the United States this fall....

21.08.25 - 14:18	Nuwellis Receives FDA 510(k) Clearance for New Dual Lumen Extended Length Catheter (GlobeNewswire EN)
	MINNEAPOLIS, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on fluid management, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for a new size of its Dual Lumen Extended Length Catheter (dELC)....

19.08.25 - 14:36	Nuwellis signs letter of intent to acquire Rendiatech (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

19.08.25 - 14:18	Nuwellis Signs Letter of Intent to Explore Acquisition of Rendiatech Ltd., A Real-Time Fluid Monitoring Company (GlobeNewswire EN)
	Proposed acquisition supports strategy to drive technology expansion of fluid management offering to include continuous renal health monitoring technologies supporting the full patient journey, from early risk assessment to targeted fluid removal...

15.08.25 - 14:18	Nuwellis, Inc. to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech (GlobeNewswire EN)
	Live video webcast on Thursday, August 21st at 2:40 PM ET Live video webcast on Thursday, August 21st at 2:40 PM ET...

14.08.25 - 20:42	Nuwellis outlines Q3 recovery and strategic shift after resolving $400,000 back order (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

14.08.25 - 14:30	Nuwellis GAAP EPS of -$60.99, revenue of $1.73M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

14.08.25 - 14:18	Nuwellis, Inc. Reports Second Quarter 2025 Financial Results and Business Highlights (GlobeNewswire EN)
	MINNEAPOLIS, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a commercial-stage medical technology company dedicated to transforming care for fluid overload patients, today announced financial results for the second quarter ended June 30, 2025, and provided a business update....

07.07.25 - 08:24	XFRA: 22S0: Aussetzung/Suspension (XETRA)
	DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT: THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT: INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL NUWELLIS COM NEW DL-,0001 22S0 US67113Y7022 BAW/UFN...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Der Mensch ward zum Tun und nicht zum Vernünfteln erschaffen. Aber eben deswegen, weil er nicht dazu erschaffen ward, hängt er diesem mehr als jenem nach. - Gotthold Ephraim Lessing

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram